Amyloid and Tau Biomarkers in Subjective Cognitive Impairment

Journal of Alzheimer's Disease

Volumn 47, Issue 1, 2015, Pages 1-8

  Colijn, Mark A ^a   Grossberg, George T ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Amyloid; Biological markers; Dementia; Mild cognitive impairment; Pittsburgh compound B; Positron emission tomography; Prodromal symptoms; Tau proteins; Tauopathies

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; BIOLOGICAL MARKER; TAU PROTEIN; 2-(4'-(METHYLAMINO)PHENYL)-6-HYDROXYBENZOTHIAZOLE; ANILINE DERIVATIVE; THIAZOLE DERIVATIVE;

ALZHEIMER DISEASE; COGNITIVE DEFECT; DISEASE COURSE; EXECUTIVE FUNCTION; FRACTIONAL ANISOTROPY; GENETIC RISK; HUMAN; LONGITUDINAL STUDY; MILD COGNITIVE IMPAIRMENT; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; REVIEW; SUBJECTIVE COGNITIVE IMPAIRMENT; BIBLIOGRAPHIC DATABASE; CROSS-SECTIONAL STUDY; METABOLISM; SCINTISCANNING;

AMYLOID BETA-PEPTIDES; ANILINE COMPOUNDS; BIOMARKERS; CROSS-SECTIONAL STUDIES; DATABASES, BIBLIOGRAPHIC; HUMANS; LONGITUDINAL STUDIES; MILD COGNITIVE IMPAIRMENT; POSITRON-EMISSION TOMOGRAPHY; TAU PROTEINS; THIAZOLES;

EID: 84940906992     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-150180     Document Type: Review

References (53)

1. Jessen F (2014) Subjective and objective cognitive decline at the pre-dementia stage of Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci 264(Suppl 1), S3-S7.
2. Jessen F, Wiese B, Bachmann C, Eifflaender-Gorfer S, Haller F, Kolsch H, Luck T, Mosch E, van den Bussche H, Wagner M, Wollny A, Zimmermann T, Pentzek M, Riedel- Heller SG, Romberg HP,Weyerer S, Kaduszkiewicz H, Maier W, Bickel H, German Study on Aging C, Dementia in Primary Care Patients Study G (2010) Prediction of dementia by subjective memory impairment: Effects of severity and temporal association with cognitive impairment. Arch Gen Psychiatry 67, 414-422.
3. Reisberg B, Shulman MB,Torossian C, Leng L, ZhuW(2010) Outcome over seven years of healthy adults with and without subjective cognitive impairment. Alzheimers Dement 6, 11-24.
4. Ferreira D, Rivero-Santana A, Perestelo-Perez L,Westman E, Wahlund LO, Sarria A, Serrano-Aguilar P (2014) Improving CSF biomarkers' performance for predicting progression from mild cognitive impairment to Alzheimer's disease by considering different confounding factors: A meta-analysis. Front Aging Neurosci 6, 287.
5. Cohen AD, Klunk WE (2014) Early detection of Alzheimer's disease using PiB and FDG PET. Neurobiol Dis 72PA, 117-122.
6. Ferreira D, Perestelo-Perez L, Westman E, Wahlund LO, Sarria A, Serrano-Aguilar P (2014) Meta-review of CSF core biomarkers in Alzheimer's disease: The state-of-the-art after the new revised diagnostic criteria. Front Aging Neurosci 6, 47.
7. Jack CR, Jr., Holtzman DM (2013) Biomarker modeling of Alzheimer's disease. Neuron 80, 1347-1358.
8. Rodda J, Okello A, Edison P, Dannhauser T, Brooks DJ, Walker Z (2010) (11)C-PIB PET in subjective cognitive impairment. Eur Psychiatry 25, 123-125.
9. Chetelat G, Villemagne VL, Bourgeat P, Pike KE, Jones G, Ames D, Ellis KA, Szoeke C, Martins RN, O'Keefe GJ, Salvado O, Masters CL, Rowe CC, Australian Imaging B, Lifestyle Research G (2010) Relationship between atrophy and beta-amyloid deposition in Alzheimer disease. Ann Neurol 67, 317-324.
10. Ivanoiu A, Dricot L, Gilis N, Grandin C, Lhommel R, Quenon L, Hanseeuw B (2015) Classification of nondemented patients attending a memory clinic using the new diagnostic criteria for Alzheimer's disease with diseaserelated biomarkers. J Alzheimers Dis 43, 835-847.
11. Verdile G, Laws SM, Henley D, Ames D, Bush AI, Ellis KA, Faux NG, Gupta VB, Li QX, Masters CL, Pike KE, Rowe CC, Szoeke C, Taddei K, Villemagne VL, Martins RN, Group AR (2014) Associations between gonadotropins, testosterone and beta amyloid in men at risk of Alzheimer's disease. Mol Psychiatry 19, 69-75.
12. Amariglio RE, Becker JA, Carmasin J, Wadsworth LP, Lorius N, Sullivan C, Maye JE, Gidicsin C, Pepin LC, Sperling RA, Johnson KA, Rentz DM (2012) Subjective cognitive complaints and amyloid burden in cognitively normal older individuals. Neuropsychologia 50, 2880-2886.
13. Perrotin A, Mormino EC, Madison CM, Hayenga AO, Jagust WJ(2012) Subjective cognition and amyloid deposition imaging: APittsburgh CompoundBpositron emission tomography study in normal elderly individuals. Arch Neurol 69, 223-229.
14. Mielke MM,Wiste HJ,Weigand SD, Knopman DS, Lowe VJ, Roberts RO, Geda YE, Swenson-Dravis DM, Boeve BF, Senjem ML, Vemuri P, Petersen RC, Jack CR, Jr. (2012) Indicators of amyloid burden in a population-based study of cognitively normal elderly. Neurology 79, 1570-1577.
15. Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, Fripp J, Tochon-Danguy H, Morandeau L, O'Keefe G, Price R, Raniga P, Robins P, Acosta O, Lenzo N, Szoeke C, Salvado O, Head R, Martins R, Masters CL, Ames D, Villemagne VL (2010) Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 31, 1275-1283.
16. Buckley R, Saling MM, Ames D, Rowe CC, Lautenschlager NT, Macaulay SL, Martins RN, Masters CL, O'Meara T, Savage G, Szoeke C, Villemagne VL, Ellis KA, Australian Imaging B, Lifestyle Study of Aging Research G (2013) Factors affecting subjective memory complaints in the AIBL aging study: Biomarkers, memory, affect, and age. Int Psychogeriatr 25, 1307-1315.
17. Hollands S, Lim YY, Buckley R, Pietrzak RH, Snyder PJ, Ames D, Ellis KA, Harrington K, Lautenschlager N, Martins RN, Masters CL,Villemagne VL, Rowe CC, Maruff P (2015) Amyloid-beta related memory decline is not associated with subjective or informant rated cognitive impairment in healthy adults. J Alzheimers Dis 43, 677-686.
18. Sole-Padulles C, Llado A, Bartres-Faz D, Fortea J, Sanchez- Valle R, Bosch B, Antonell A, Molinuevo JL, Rami L (2011) Association between cerebrospinal fluid tau and brain atrophy is not related to clinical severity in the Alzheimer's disease continuum. Psychiatry Res 192, 140-146.
19. Rami L, Fortea J, Bosch B, Sole-Padulles C, Llado A, Iranzo A, Sanchez-Valle R, Molinuevo JL (2011) Cerebrospinal fluid biomarkers and memory present distinct associations along the continuum from healthy subjects to AD patients. J Alzheimers Dis 23, 319-326.
20. Antonell A, Fortea J, Rami L, Bosch B, Balasa M, Sanchez- Valle R, Iranzo A, Molinuevo JL, Llado A (2011) Different profiles of Alzheimer's disease cerebrospinal fluid biomarkers in controls and subjects with subjective memory complaints. J Neural Transm 118, 259-262.
21. Fortea J, Sala-Llonch R, Bartres-Faz D, Llado A, Sole- Padulles C, Bosch B, Antonell A, Olives J, Sanchez-Valle R, Molinuevo JL, Rami L (2011) Cognitively preserved subjects with transitional cerebrospinal fluid ss-amyloid 1-42 values have thicker cortex in Alzheimer's disease vulnerable areas. Biol Psychiatry 70, 183-190.
22. Visser PJ, Verhey F, Knol DL, Scheltens P, Wahlund LO, Freund-LeviY, Tsolaki M, Minthon L,Wallin AK, Hampel H, Burger K, Pirttila T, Soininen H, Rikkert MO, Verbeek MM, Spiru L, Blennow K (2009) Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: A prospective cohort study. Lancet Neurol 8, 619-627.
23. Leoni V, Solomon A, Lovgren-Sandblom A, Minthon L, Blennow K, Hansson O, Wahlund LO, Kivipelto M, Bjorkhem I (2013) Diagnostic power of 24S-hydroxy cholesterol in cerebrospinal fluid: Candidate marker of brain health. J Alzheimers Dis 36, 739-747.
24. Solomon A, Leoni V, Kivipelto M, Besga A, Oksengard AR, Julin P, Svensson L, Wahlund LO, Andreasen N, Winblad B, Soininen H, Bjorkhem I (2009) Plasma levels of 24S-hydroxycholesterol reflect brain volumes in patients without objective cognitive impairment but not in those with Alzheimer's disease. Neurosci Lett 462, 89-93.
25. Hooshmand B, Lokk J, Solomon A, Mangialasche F, Miralbell J, Spulber G, Annerbo S, Andreasen N,Winblad B, Cedazo-Minguez A, Wahlund LO, Kivipelto M (2014) Vitamin D in relation to cognitive impairment, cerebrospinal fluid biomarkers, and brain volumes. J Gerontol A Biol Sci Med Sci 69, 1132-1138.
26. Gil-Bea FJ, Solas M, Solomon A, Mugueta C, Winblad B, Kivipelto M, Ramirez MJ, Cedazo-Minguez A (2010) Insulin levels are decreased in the cerebrospinal fluid of women with prodomal Alzheimer's disease. J Alzheimers Dis 22, 405-413.
27. Almkvist O, Tallberg IM (2009) Cognitive decline from estimated premorbid status predicts neurodegeneration in Alzheimer's disease. Neuropsychology 23, 117-124.
28. Selnes P, Aarsland D, Bjornerud A, Gjerstad L, Wallin A, Hessen E, Reinvang I, Grambaite R, Auning E, Kjaervik VK, Due-Tonnessen P, Stenset V, Fladby T (2013) Diffusion tensor imaging surpasses cerebrospinal fluid as predictor of cognitive decline and medial temporal lobe atrophy in subjective cognitive impairment and mild cognitive impairment. J Alzheimers Dis 33, 723-736.
29. Grambaite R, Hessen E, Auning E, Aarsland D, Selnes P, Fladby T (2013) Correlates of subjective and mild cognitive impairment: Depressive symptoms and CSF biomarkers. Dement Geriatr Cogn Dis Extra 3, 291-300.
30. Auning E, Selnes P, Grambaite R, Saltyte Benth J, Haram A, Lovli Stav A, Bjornerud A, Hessen E, Hol PK, Muftuler Londalen A, Fladby T, Aarsland D (2015) Neurobiological correlates of depressive symptoms in people with subjective and mild cognitive impairment. Acta Psychiatr Scand 131, 139-147.
31. Damian M, Hausner L, Jekel K, Richter M, Froelich L, Almkvist O, Boada M, Bullock R, De Deyn PP, Frisoni GB, Hampel H, Jones RW, Kehoe P, Lenoir H, Minthon L, Olde Rikkert MG, Rodriguez G, Scheltens P, Soininen H, Spiru L, Touchon J, Tsolaki M, Vellas B, Verhey FR, Winblad B, Wahlund LO, Wilcock G, Visser PJ (2013) Single-domain amnestic mild cognitive impairment identified by cluster analysis predicts Alzheimer's disease in the European prospective DESCRIPA study. Dement Geriatr Cogn Disord 36, 1-19.
32. Maruyama M, Matsui T, Tanji H, Nemoto M, Tomita N, Ootsuki M, Arai H, Sasaki H (2004) Cerebrospinal fluid tau protein and periventricular white matter lesions in patients with mild cognitive impairment: Implications for 2 major pathways. Arch Neurol 61, 716-720.
33. Schoonenboom NS, Reesink FE, Verwey NA, Kester MI, Teunissen CE, van de Ven PM, Pijnenburg YA, Blankenstein MA, Rozemuller AJ, Scheltens P, van der Flier WM (2012) Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology 78, 47-54.
34. Jochemsen HM, Teunissen CE, Ashby EL, van der Flier WM, Jones RE, Geerlings MI, Scheltens P, Kehoe PG, Muller M (2014) The association of angiotensin-converting enzyme with biomarkers for Alzheimer's disease. Alzheimers Res Ther 6, 27.
35. Mulder C, Wahlund LO, Teerlink T, Blomberg M, Veerhuis R, van Kamp GJ, Scheltens P, Scheffer PG (2003) Decreased lysophosphatidylcholine/phosphatidylcholine ratio in cerebrospinal fluid in Alzheimer's disease. J Neural Transm 110, 949-955.
36. Kramberger MG, Jelic V, Kareholt I, Enache D, Eriksdotter Jonhagen M, Winblad B, Aarsland D (2012) Cerebrospinal fluid Alzheimer markers in depressed elderly subjects with and without Alzheimer's disease. Dement Geriatr Cogn Dis Extra 2, 48-56.
37. Senanarong V, Siwasariyanon N, Washirutmangkur L, Poungvarin N, Ratanabunakit C, Aoonkaew N, Udomphanthurak S (2012) Alzheimer's disease dementia as the diagnosis best supported by the cerebrospinal fluid biomarkers: Difference in cut-off levels from thai experience. Int J Alzheimers Dis 2012, 212063.
38. Kester MI, Goos JD, Teunissen CE, Benedictus MR, Bouwman FH, Wattjes MP, Barkhof F, Scheltens P, van der FlierWM(2014) Associations between cerebral small-vessel disease and Alzheimer disease pathology as measured by cerebrospinal fluid biomarkers. JAMA Neurol 71, 855-862.
39. Mosconi L, De Santi S, Brys M, Tsui WH, Pirraglia E, Glodzik-Sobanska L, Rich KE, Switalski R, Mehta PD, Pratico D, Zinkowski R, Blennow K, de Leon MJ (2008) Hypometabolism and altered cerebrospinal fluid markers in normal apolipoprotein E E4 carriers with subjective memory complaints. Biol Psychiatry 63, 609-618.
40. Frisoni GB, Prestia A, Zanetti O, Galluzzi S, Romano M, Cotelli M, Gennarelli M, Binetti G, Bocchio L, Paghera B, Amicucci G, Bonetti M, Benussi L, Ghidoni R, Geroldi C (2009) Markers of Alzheimer's disease in a population attending a memory clinic. Alzheimers Dement 5, 307-317.
41. van Harten AC, Visser PJ, Pijnenburg YA, Teunissen CE, Blankenstein MA, Scheltens P, van der Flier WM (2013) Cerebrospinal fluid Abeta42 is the best predictor of clinical progression in patients with subjective complaints. Alzheimers Dement 9, 481-487.
42. Rolstad S, Berg AI, Bjerke M, Johansson B, Zetterberg H, Wallin A (2013) Cerebrospinal fluid biomarkers mirror rate of cognitive decline. J Alzheimers Dis 34, 949-956.
43. Stomrud E, Hansson O, Blennow K, Minthon L, Londos E (2007) Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly. Dement Geriatr Cogn Disord 24, 118-124.
44. Striepens N, Scheef L, Wind A, Popp J, Spottke A, Cooper- Mahkorn D, Suliman H, Wagner M, Schild HH, Jessen F (2010) Volume loss of the medial temporal lobe structures in subjective memory impairment. Dement Geriatr Cogn Disord 29, 75-81.
45. Scheef L, Spottke A, Daerr M, Joe A, Striepens N, Kolsch H, Popp J, Daamen M, Gorris D, Heneka MT, Boecker H, Biersack HJ, Maier W, Schild HH, Wagner M, Jessen F (2012) Glucose metabolism, gray matter structure, and memory decline in subjective memory impairment. Neurology 79, 1332-1339.
46. Hafkemeijer A, Altmann-Schneider I, Oleksik AM, van de Wiel L, Middelkoop HA, van Buchem MA, van der Grond J, Rombouts SA (2013) Increased functional connectivity and brain atrophy in elderly with subjective memory complaints. Brain Connect 3, 353-362.
47. Kim MJ, Seo SW, Kim GH, Kim ST, Lee JM, Qiu A, Na DL (2013) Less depressive symptoms are associated with smaller hippocampus in subjective memory impairment. Arch Gerontol Geriatr 57, 110-115.
48. Cherbuin N, Sargent-Cox K, Easteal S, Sachdev P, Anstey KJ (2015) Hippocampal atrophy is associated with subjective memory decline: The PATHThrough Life Study.AmJ Geriatr Psychiatry 23, 446-455.
49. Shin J, Kepe V, Barrio JR, Small GW (2011) The merits of FDDNP-PET imaging in Alzheimer's disease. J Alzheimers Dis 26(Suppl 3), 135-145.
50. Villemagne VL, Rowe CC (2013) Long night's journey into the day: Amyloid-beta imaging in Alzheimer's disease. J Alzheimers Dis 33(Suppl 1), S349-S359.
51. Modrego PJ (2006) Predictors of conversion to dementia of probable Alzheimer type in patients with mild cognitive impairment. Curr Alzheimer Res 3, 161-170.
52. Mulder C, Verwey NA, van der Flier WM, Bouwman FH, Kok A, van Elk EJ, Scheltens P, Blankenstein MA (2010) Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. Clin Chem 56, 248-253.
53. Chetelat G, Villemagne VL, Pike KE, Baron JC, Bourgeat P, Jones G, Faux NG, Ellis KA, Salvado O, Szoeke C, Martins RN, Ames D, Masters CL, Rowe CC, Australian Imaging B, Lifestyle Study of Ageing Research G (2010) Larger temporal volume in elderly with high versus low betaamyloid deposition. Brain 133, 3349-3358.